702. CAR-T Cell Therapies: Basic and Translational: Poster III

Signaling role of viral protein motif and its application in CAR T cell therapy

Folate receptor beta targeting of tumor associated macrophages improves lymphoma cell responses to CD19 CAR T cells

Identification and functional characterization of a novel best in class anti CD79b CAR T cell immunotherapy using a multidimensional screening strategy

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome pyroptosis signaling

CD7 negative T cell immune reconstitution after CD7 targted CAR T cell therapy

In silico design of degron tags for precise modulation of CAR T cell activity using clinically utilized drugs

Stimulated CAR T cells from non Hodgkin lymphomas patients engage and activate monocytes via extracellular vesicles

A functional CAR T cell atlas to unravel regulatory mechanisms of CAR T therapies

Off the shelf CD117 CAR iNKT cells as a safe and effective allogeneic immunotherapy targeting AML and its immunosuppressive microenvironment

M6A driven control of T cell fitness via lrpprc defines a novel regulatory axis to enhance adoptive cell therapy

BRD4 sustains immunosuppressive erythroid precursors to compromise CAR T cell function

Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR T

Targeting CSF1R to overcome myeloid cell suppression in CART therapy

Dynamic changes in the bone marrow niche following CD19 targeted CAR T cell infusion in diffuse large B cell lymphoma DLBCL

IL 2 mutein mediated improvement of CAR T function in Relapsed Refractory diffuse B cell lymphoma

Triple base edited dual targeting CD70 33 CAR T cells to avoid cytokine mediated resistance in Acute Myeloid Leukemia

Dex and IL 7 enhance persistence of CAR T cells to promote long term remission in mouse models of multiple myeloma

CAR T cells targeting CD79b and CD19 exhibit robust antitumour activity against B cell lymphoma

IMV101 a novel CD19 targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinical models

Metabolic pathway signatures unpinning response to CD19 CAR T cell therapy in aggressive B cell non Hodgkin s lymphoma